Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Tax Provisions: 2023-2024

Historic Tax Provisions for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $2.6 million.

  • Monte Rosa Therapeutics' Tax Provisions fell 4574.65% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 158.85%. This contributed to the annual value of $2.6 million for FY2024, which is 669.23% up from last year.
  • Monte Rosa Therapeutics' Tax Provisions amounted to $2.6 million in FY2024, which was up 669.23% from $338,000 recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Tax Provisions peaked at $2.6 million during FY2024, and registered a low of $338,000 during FY2023.
  • Its 2-year average for Tax Provisions is $1.5 million, with a median of $1.5 million in 2023.
  • Data for Monte Rosa Therapeutics' Tax Provisions shows a peak YoY soared of 669.23% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Tax Provisions (Yearly) stood at $338,000 in 2023, then soared by 669.23% to $2.6 million in 2024.